全國服務咨詢熱線：
18860915427
18860915427
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 95635-55-5 |
|---|---|---|---|
| 分子式 | C24H33N3O4 | 純度 | 98% |
| 分子量 | 427.54 | 貨號 | abs47028329 |
| 規格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | used to treat chronic angina | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
Ranolazine 95635-55-5
| 產品描述 | |
| 描述 | Ranolazine 2HCl is a calcium uptake inhibitor via the sodium/calcium channal, used to treat chronic angina. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 雷諾嗪；CVT 303；RS 43285-003 |
| 外觀 | 白色或類白色結晶性粉末 |
| 可溶性/溶解性 | DMSO : 80 mg/mL (187.1 mM) Ethanol : 16 mg/mL (37.4 mM) |
| 生物活性 | |
| 靶點 | Calcium channel |
| In vitro(體外研究) | Ranolazine is found to bind more tightly to the inactivated state than the resting state of the sodium channel underlying I(NaL), with apparent dissociation constants K(dr)=7.47 mM and K(di)=1.71 mM, respectively. Ranolazine at 5 mM and 10 mM reversibly shortens the duration of TCs and abolishes the after contraction. Ranolazine inhibits the late component of INa and attenuates prolongation of action potential duration when late INa is increased, both in the absence and presence of IK-blocking drugs. Ranolazine (10 mM) reduces by 89% the 13.6-fold increase in variability of APD caused by 10 nM ATX-II. |
| In vivo(體內研究) | Ranolazine significantly and reversibly shortens the action potential duration (APD) of myocytes stimulated at either 0.5 or 0.25 Hz in a concentration-dependent manner in left ventricular myocytes of dogs. Ranolazine (10 mM) significantly increases glucose oxidation 1.5-fold to 3-fold under conditions in which the contribution of glucose to overall ATP production is low (low Ca, high FA, with insulin), high (high Ca, low Fa, with pacing), or intermediate in working heart of rats. Ranolazine (10 mM) similarly increases glucose oxidation in normoxic Langendorff hearts (high Ca, low FA; 15 mL/min) of rats. Ranolazine significantly improves functional outcome in reperfused ischemic working hearts, which is associated with significant increases in glucose oxidation. |
| 參考文獻 | |
| 參考文獻 |
| 研究領域 | |
| 研究領域 | Cardiovascular CancerCancer Metabolism CancerTumor biomarkers Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
電話
微信掃一掃
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：fengmj@univ-bio.com
傳真：